P1 · PANEL / ROI / AXIS GROUND TRUTH
原 EXE 对齐基准真值复核
所有保存均写入追加式审计事件;旧标注、旧比较和旧提取结果不会被删除或覆盖。
multi_curve
pending
PMID 40454705
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
F4 · Panel Event-Free_Survival_According_to_Investigator_Assessment · Event-Free Survival
Figure 4.. Event-Free Survival, According to Investigator Assessment. The figure shows Kaplan–Meier estimates of EFS among patients in the full analysis set. EFS was measured from the time of randomization. Tick marks indicate censored data, and the vertical lines indicate landmark analyses of EFS at 6- and 12-months following randomization. An event was defined as the first of the following: documented disease progression that precluded surgery or prevented completion of definitive surgery; disease recurrence or a new lesion, local or distant, post-surgery (a new primary malignancy, confirmed by pathology if clinically feasible, was not considered to be an EFS event); for patients who did not undergo surgery for reasons other than disease progression, documented disease progression after the neoadjuvant period; discovery upon attempting surgery that the surgery could not be completed due to disease progression; or death due to any cause. At the interim analysis of EFS, the median duration of follow-up for EFS in all patients was 14.3 (range, < 0.1 to 41.9), 18.3 (range, 2.1 to 41.9), and 14.3 (range, 1.7 to 41.8) months for the osimertinib-plus-chemotherapy, osimertinib-monotherapy, and placebo-plus-chemotherapy groups, respectively; the median duration of follow-up for EFS in censored patients was 15.9 (range, < 0.1 to 41.9), 18.3 (range, 2.2 to 41.9) and 18.8 months (range, 1.7 to 41.8) for each group, respectively. *A 99.8% CI for the HR is presented for the comparison of the osimertinib-plus-chemotherapy versus placebo-plus-chemotherapy; as a statistically significant improvement was not reached for this comparison (a p value < 0.002 was required to declare statistical significance), the treatment difference in EFS between the osimertinib-monotherapy group and the placebo-plus-chemotherapy group was not formally tested. † A 95% CI for the HR is presented for the comparison of osimertinib-monotherapy versus placebo-plus-chemotherapy. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NC, not calculable; NR, not reached.坐标框复核
洋红 = 当前 Linux 候选;绿色 = 已保存人工真值。没有绿色框表示仍未形成真值。
当前候选 {'x0': 235, 'y0': 227, 'x1': 1042, 'y1': 482}
人工真值 {'x0': 235, 'x1': 1042, 'y0': 227, 'y1': 482}
查看候选 OCR 与警告(只能作种子,不能自证真值)
{
"complete": true,
"engine": "RapidOCR",
"plot_bottom": 481,
"plot_left": 235,
"plot_right": 1041,
"plot_top": 227,
"warnings": [],
"x_axis_y": 481,
"x_confidence": 0.983,
"x_detected": true,
"x_max": 42,
"x_min": 0,
"x_ticks": [
{
"box": [
[
228.0,
494.0
],
[
241.0,
494.0
],
[
241.0,
513.0
],
[
228.0,
513.0
]
],
"confidence": 0.9582086801528931,
"pixel": 234.5,
"text": "0",
"value": 0.0
},
{
"box": [
[
284.0,
494.0
],
[
300.0,
494.0
],
[
300.0,
515.0
],
[
284.0,
515.0
]
],
"confidence": 0.9992148876190186,
"pixel": 292.0,
"text": "3",
"value": 3.0
},
{
"box": [
[
342.0,
494.0
],
[
357.0,
494.0
],
[
357.0,
513.0
],
[
342.0,
513.0
]
],
"confidence": 0.9993805885314941,
"pixel": 349.5,
"text": "6",
"value": 6.0
},
{
"box": [
[
453.0,
493.0
],
[
477.0,
493.0
],
[
477.0,
514.0
],
[
453.0,
514.0
]
],
"confidence": 0.9995485246181488,
"pixel": 465.0,
"text": "12",
"value": 12.0
},
{
"box": [
[
511.0,
493.0
],
[
535.0,
493.0
],
[
535.0,
514.0
],
[
511.0,
514.0
]
],
"confidence": 0.9998426735401154,
"pixel": 523.0,
"text": "15",
"value": 15.0
},
{
"box": [
[
568.0,
493.0
],
[
593.0,
493.0
],
[
593.0,
514.0
],
[
568.0,
514.0
]
],
"confidence": 0.9996470510959625,
"pixel": 580.5,
"text": "18",
"value": 18.0
},
{
"box": [
[
624.0,
493.0
],
[
650.0,
493.0
],
[
650.0,
514.0
],
[
624.0,
514.0
]
],
"confidence": 0.9998635053634644,
"pixel": 637.0,
"text": "21",
"value": 21.0
},
{
"box": [
[
682.0,
493.0
],
[
708.0,
493.0
],
[
708.0,
514.0
],
[
682.0,
514.0
]
],
"confidence": 0.9998856782913208,
"pixel": 695.0,
"text": "24",
"value": 24.0
},
{
"box": [
[
741.0,
493.0
],
[
766.0,
493.0
],
[
766.0,
514.0
],
[
741.0,
514.0
]
],
"confidence": 0.9997954368591309,
"pixel": 753.5,
"text": "27",
"value": 27.0
},
{
"box": [
[
798.0,
493.0
],
[
823.0,
493.0
],
[
823.0,
514.0
],
[
798.0,
514.0
]
],
"confidence": 0.9998002648353577,
"pixel": 810.5,
"text": "30",
"value": 30.0
},
{
"box": [
[
856.0,
493.0
],
[
882.0,
493.0
],
[
882.0,
514.0
],
[
856.0,
514.0
]
],
"confidence": 0.9998880624771118,
"pixel": 869.0,
"text": "33",
"value": 33.0
},
{
"box": [
[
914.0,
493.0
],
[
939.0,
493.0
],
[
939.0,
514.0
],
[
914.0,
514.0
]
],
"confidence": 0.9997755289077759,
"pixel": 926.5,
"text": "36",
"value": 36.0
},
{
"box": [
[
971.0,
493.0
],
[
996.0,
493.0
],
[
996.0,
514.0
],
[
971.0,
514.0
]
],
"confidence": 0.9994467198848724,
"pixel": 983.5,
"text": "39",
"value": 39.0
},
{
"box": [
[
1029.0,
493.0
],
[
1049.0,
493.0
],
[
1049.0,
515.0
],
[
1029.0,
515.0
]
],
"confidence": 0.9995059967041016,
"pixel": 1039.0,
"text": "42",
"value": 42.0
}
],
"y_axis_x": 234,
"y_confidence": 0.994,
"y_detected": true,
"y_max": 100,
"y_min": 0,
"y_ticks": [
{
"box": [
[
192.0,
218.0
],
[
225.0,
218.0
],
[
225.0,
237.0
],
[
192.0,
237.0
]
],
"confidence": 0.9992208083470663,
"pixel": 227.5,
"text": "100",
"value": 100.0
},
{
"box": [
[
200.0,
242.0
],
[
225.0,
242.0
],
[
225.0,
263.0
],
[
200.0,
263.0
]
],
"confidence": 0.9996223151683807,
"pixel": 252.5,
"text": "90",
"value": 90.0
},
{
"box": [
[
201.0,
267.0
],
[
225.0,
267.0
],
[
225.0,
289.0
],
[
201.0,
289.0
]
],
"confidence": 0.998892068862915,
"pixel": 278.0,
"text": "80",
"value": 80.0
},
{
"box": [
[
201.0,
293.0
],
[
225.0,
293.0
],
[
225.0,
314.0
],
[
201.0,
314.0
]
],
"confidence": 0.9995079040527344,
"pixel": 303.5,
"text": "70",
"value": 70.0
},
{
"box": [
[
201.0,
318.0
],
[
225.0,
318.0
],
[
225.0,
339.0
],
[
201.0,
339.0
]
],
"confidence": 0.9995079338550568,
"pixel": 328.5,
"text": "60",
"value": 60.0
},
{
"box": [
[
201.0,
344.0
],
[
225.0,
344.0
],
[
225.0,
366.0
],
[
201.0,
366.0
]
],
"confidence": 0.9997099339962006,
"pixel": 355.0,
"text": "50",
"value": 50.0
},
{
"box": [
[
201.0,
370.0
],
[
225.0,
370.0
],
[
225.0,
390.0
],
[
201.0,
390.0
]
],
"confidence": 0.9996252954006195,
"pixel": 380.0,
"text": "40",
"value": 40.0
},
{
"box": [
[
201.0,
395.0
],
[
225.0,
395.0
],
[
225.0,
416.0
],
[
201.0,
416.0
]
],
"confidence": 0.9996793866157532,
"pixel": 405.5,
"text": "30",
"value": 30.0
},
{
"box": [
[
200.0,
421.0
],
[
225.0,
421.0
],
[
225.0,
442.0
],
[
200.0,
442.0
]
],
"confidence": 0.9996581077575684,
"pixel": 431.5,
"text": "20",
"value": 20.0
},
{
"box": [
[
201.0,
445.0
],
[
227.0,
445.0
],
[
227.0,
466.0
],
[
201.0,
466.0
]
],
"confidence": 0.9996056854724884,
"pixel": 455.5,
"text": "10",
"value": 10.0
},
{
"box": [
[
209.0,
471.0
],
[
228.0,
471.0
],
[
228.0,
491.0
],
[
209.0,
491.0
]
],
"confidence": 0.9423633813858032,
"pixel": 481.0,
"text": "0",
"value": 0.0
}
]
}
追加一条审查结论
选择“有效 KM”时,四边 ROI、四个坐标范围、Panel、终点和曲线数均为必填。
追加式审计历史
最新事件仅作为当前缓存;以下每一条既往结论都永久保留。
| 事件 | 时间 / 审查人 | 状态 | ROI | 坐标 | 说明 |
|---|---|---|---|---|---|
| #63p1-visual-axis-audit-v2 · frozen benchmark contact sheets + original images + RapidOCR re-audit | 2026-07-28T15:12:18+00:00Codex-assisted visual audit | valid_km | {'x0': 235, 'x1': 1042, 'y0': 227, 'y1': 482} |
X 0.0–42.0 / Y 0.0–100.0 |
P1 冻结原图审查;RapidOCR 刻度重审 + 联系表视觉核验;ROI 四边按可见坐标轴框记录。 |
最近一次正式比较
Suite #3 · 2026-07-28T15:15:12+00:00
真值完整 117 / 120;通过 0;缺真值 0;无效案例 3。



